首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches
【24h】

Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches

机译:经过验证的GC-MS分析,用于确定应用的Durogesic(R)储库和Durogesic(R)D-Trans(R)基质透皮芬太尼贴剂中的残留芬太尼

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The method development and validation characteristics are described of a simple gas chromatographic-mass spectrometric (GC-MS) analytical procedure to determine residual fentanyl in used Durogesic (R) reservoir patches and Durogesic (R) D-Trans (R) matrix technology based systems to estimate the actual rate of transdermal fentanyl delivered in individual patients. The sample preparation protocol constituting a saline based extraction of sets of new patches of each nominal dose available, resulted in fentanyl extraction recoveries to increase steadily as a function of. increasing extraction time. For the reservoir type transdermal therapeutic system (TTS), fentanyl extraction efficiencies at equilibrium (16h) ranged from approximately 60% (100-mu g/h TTS) to 95% (25-mu g/h TTS), whereas for the matrix type system considerable lower recoveries were demonstrated for the highest nominal dose rates (35%-52%), while reaching 90% for the 25-mu g/h system. For the latter type of fentanyl TTS, an optimized methanol based extraction protocol yielded virtually quantitative fentanyl recoveries for each matrix patch nominal dose level at substantially shorter extraction periods (15 min). The GC-MS analytical method using selected ion monitoring (SIM) and deuterated fentanyl as internal standard was shown to be adequately selective with regard to the presence of other compounds in the Durogesic (R) patches. It was further demonstrated that the developed analytical protocols provided highly reproducible and accurate estimates of the initial fentanyl content of each patch type at all available nominal doses, with coefficients of variation and relative errors generally below 10%. These advantageous assay validation characteristics can be further transposed to the application of residual fentanyl level estimates in used patches, provided that with each batch of samples also a set of new TTSs with equal dose is assayed to perfectly mimic extraction phenomena. Finally, the presented GC-MS analytical protocol was successfully applied for the determination of residual fentanyl in a subset of 57 reservoir type patches obtained from four palliative patients. (c) 2006 Elsevier B.V. All rights reserved.
机译:描述了一种简单的气相色谱-质谱(GC-MS)分析程序的方法开发和验证特征,该程序可确定使用过的Durogesic(R)储层和基于Durogesic(R)D-Trans(R)基质技术的系统中的残留芬太尼估计个别患者中透皮芬太尼的实际递送率。样品制备方案构成了对每个可用标称剂量的新贴剂组进行基于盐水的提取,从而导致芬太尼提取回收率随着功能的增加而稳定增加。增加提取时间。对于储库类型的透皮治疗系统(TTS),在平衡状态(16h)时芬太尼的提取效率范围从大约60%(100μg / h TTS)到95%(25μg / h TTS),而对于基质对于最高的标称剂量率(35%-52%),证实了这种类型的系统具有较低的回收率,而对于25μg/ h的系统,则达到了90%。对于后一种类型的芬太尼TTS,基于甲醇的优化提取方案可在实质上更短的提取时间(15分钟)内对每种基质补丁标称剂量水平产生几乎定量的芬太尼回收率。对于使用Durogesic(R)贴片中的其他化合物,使用选定的离子监测(SIM)和氘代芬太尼作为内标的GC-MS分析方法显示出足够的选择性。进一步证明,在所有可用的标称剂量下,开发的分析规程提供了每种贴剂类型的初始芬太尼含量的高度可重复且准确的估计值,变异系数和相对误差通常低于10%。这些有利的测定验证特征可以进一步转换为在使用过的贴剂中应用残留的芬太尼水平估算值,只要对每批样品还测定了一组等剂量的新TTS,以完美模拟提取现象。最后,提出的GC-MS分析规程已成功用于测定从四名姑息患者获得的57个储库型斑块中的残留芬太尼。 (c)2006 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号